Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

September 22, 2017: By Jon Swedien

GraybugGraybug Vision has begun dosing patients in a Phase I/II clinical trial for GB-102, its lead product candidate for wet age-related macular degeneration (AMD), the Redwood City, California, company announced Sept. 19.

GB-102 is a novel intravitreal (IVT) injectable depot formulation of sunitinib malate, a tyrosine kinase inhibitor that blocks multiple angiogenesis pathways. GB-102 has the potential to be a twice annual treatment for wet AMD, Graybug said.

The two-part study—ADAGIO—will evaluate wet AMD patients currently being treated with available IVT anti-VEGF agents who are then switched over to treatment with GB-102 alone, Graybug said.

Part one is a multicenter, open-label, single IVT injection study of up to four dose levels of GB-102 administered in ascending dosing cohorts, Graybug said. Following the single IVT injection of GB-102, patients will undergo monthly evaluation for eight months to assess safety, tolerability, and functional/pharmacodynamic parameters, including visual acuity and optical coherence tomography (OCT) measures of the retina, Graybug said.

Part two is a multicenter, double-masked, randomized, parallel-group, safety, and efficacy evaluation of repeated IVT injections of two dose levels of GB-102 compared with a standard IVT regimen of aflibercept, Graybug said.

Graybug said it also has a second-generation product under development, GB-103, that has potential to be a once-per-year IVT treatment for wet AMD.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022